载脂蛋白C3 Sst I、T-455C、C-482T和C1100T基因多态性与冠心病风险之间的关联。
Association between apolipoprotein C3 Sst I, T-455C, C-482T and C1100T polymorphisms and risk of coronary heart disease.
作者信息
Lin Bin, Huang Yiwei, Zhang Mingying, Wang Jun, Wu Yihua
机构信息
Department of Cardiology, Wenzhou Central Hospital, Wenzhou, China.
出版信息
BMJ Open. 2014 Jan 14;4(1):e004156. doi: 10.1136/bmjopen-2013-004156.
OBJECTIVES
Apolipoprotein C3 (ApoC3) polymorphisms have been suggested to be associated with risk of coronary heart disease (CHD). However, the results of relevant studies were inconsistent. We aimed to systematically evaluate this issue.
DESIGN
PubMed, EMBASE and Cochrane library databases (up to March 2013) were systematically searched to identify studies evaluating the association between ApoC3 polymorphisms and CHD risk. Two reviewers independently identified studies, extracted and analysed the data. Either a fixed-effects or a random-effects model was adopted to estimate overall ORs.
STUDIES REVIEWED
Finally, 20 studies comprising 15 591 participants were included in this systematic review. Fifteen studies with 11 539 individuals were included in the meta-analysis of Sst I polymorphism, four studies comprising 3378 individuals assessed T-455C polymorphism, four studies with 3070 participants evaluated C-482T polymorphism and C1100T polymorphism was assessed by three studies comprising 4662 participants.
RESULTS
Under dominant model, Sst I polymorphism was borderline significantly associated with CHD risk (S1S2+S2S2 vs S1S1, pooled OR=1.19, 95% CI 1.00 to 1.42). Subgroup analyses suggested that Sst I polymorphism was significantly associated with myocardial infarction (MI) risk (pooled OR=1.42, 95% CI 1.06 to 1.91), and Sst I polymorphism was statistically associated with CHD risk among Asian population (pooled OR=1.35, 95% CI 1.08 to 1.69) and in retrospective studies (pooled OR=1.30, 95% CI 1.04 to 1.61). A significant association was observed between T-455C polymorphism and CHD risk (TC+CC vs TT, pooled OR=1.22, 95% CI 1.06 to 1.42). A borderline significant association was suggested between T-455C polymorphism and MI risk (pooled OR=1.21, 95% CI 1.00 to 1.46). C-482T and C1100T polymorphisms were not indicated to be associated with CHD risk or MI risk.
CONCLUSIONS
ApoC3 Sst I and T-455C polymorphisms might be associated with CHD risk.
目的
载脂蛋白C3（ApoC3）基因多态性被认为与冠心病（CHD）风险相关。然而，相关研究结果并不一致。我们旨在系统评估这一问题。
设计
系统检索PubMed、EMBASE和Cochrane图书馆数据库（截至2013年3月），以识别评估ApoC3基因多态性与CHD风险之间关联的研究。两名评价者独立识别研究、提取和分析数据。采用固定效应或随机效应模型估计总体比值比（OR）。
纳入研究
最终，本系统评价纳入了20项研究，共15591名参与者。Sst I基因多态性的荟萃分析纳入了15项研究，共11539人；T-455C基因多态性的评估纳入了4项研究，共3378人；C-482T基因多态性和C1100T基因多态性的评估分别纳入了4项研究，共3070人，以及3项研究，共4662人。
结果
在显性模型下，Sst I基因多态性与CHD风险呈临界显著相关（S1S2+S2S2 vs S1S1，合并OR=1.19，95%CI 1.00至1.42）。亚组分析表明，Sst I基因多态性与心肌梗死（MI）风险显著相关（合并OR=1.42，95%CI 1.06至1.91），且Sst I基因多态性在亚洲人群（合并OR=1.35，95%CI 1.08至1.69）和回顾性研究（合并OR=1.30，95%CI 1.04至1.61）中与CHD风险存在统计学关联。T- 455C基因多态性与CHD风险之间存在显著关联（TC+CC vs TT，合并OR=1.22，95%CI 1.06至1.42）。T-455C基因多态性与MI风险之间存在临界显著关联（合并OR=1.21，95%CI 1.00至1.46）。未表明C-482T和C1100T基因多态性与CHD风险或MI风险相关。
结论
ApoC3 Sst I和T-455C基因多态性可能与CHD风险相关。
Zotero 插件